Shanghai Junshi Biosciences Co., Ltd. (SHA:688180)

Market Cap	26.29B -26.6%
Revenue (ttm)	3.03B +29.8%
Net Income	-440.82M
EPS	-0.41
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,720,510
Open	30.49
Previous Close	30.39
Day's Range	29.60 - 30.51
52-Week Range	28.10 - 46.55
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About SHA:688180

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 3,055
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688180

Financial Performance

In 2025, SHA:688180's revenue was 2.50 billion, an increase of 28.23% compared to the previous year's 1.95 billion. Losses were -875.17 million, -31.68% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 29, 2026

Data Sources Report a data error